Viking Therapeutics to Announce Q2 2024 Financial Results on July 24

Viking Therapeutics, Inc. (Viking), a clinical-stage biopharmaceutical firm listed on NASDAQ as VKTX, has announced that it will release its financial results for the second quarter of 2024 after the market closes on Wednesday, July 24, 2024. To discuss these financial results and provide updates on corporate developments, the company has scheduled a conference call for the same day at 4:30 p.m. Eastern Time. Interested participants can join the call by dialing (844) 850-0543 from within the U.S. or (412) 317-5199 from outside the U.S. For those unable to join live, a replay will be available until July 31, 2024, accessible by dialing (877) 344-7529 from the U.S. or (412) 317-0088 internationally, using access code #4777459. A live webcast of the call and a subsequent archive will be accessible on Viking’s website.

Viking Therapeutics is dedicated to developing innovative therapies for metabolic and endocrine disorders. Currently, the company has three compounds in various stages of clinical trials. One of these compounds, VK2809, is an orally available small molecule that acts as a selective thyroid hormone receptor beta agonist, designed for treating lipid and metabolic disorders. VK2809 successfully met both primary and secondary objectives in a recently concluded Phase 2b study aimed at treating biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. Additionally, in a Phase 2a trial targeting non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C levels, VK2809 showed statistically significant reductions in LDL-C and liver fat in patients compared to those who received a placebo.

Another compound in Viking’s pipeline is VK2735, which is being developed as a dual agonist of the GLP-1 and GIP receptors. This compound has shown promise for the potential treatment of various metabolic disorders. Data from Phase 1 and Phase 2 trials, where VK2735 was administered subcutaneously, indicated a favorable safety and tolerability profile, along with positive clinical benefits. Viking is also working on an oral formulation of VK2735, currently being evaluated in a Phase 1 trial.

In the realm of rare diseases, Viking is advancing VK0214, an orally available small molecule selective thyroid hormone receptor beta agonist aimed at treating X-linked adrenoleukodystrophy (X-ALD). VK0214 is presently under investigation in a Phase 1b clinical trial involving patients with the adrenomyeloneuropathy (AMN) form of X-ALD.

Viking Therapeutics specializes in leveraging its expertise in metabolic processes to create first-in-class or best-in-class therapeutics, with the ultimate goal of enhancing the quality of life for patients suffering from metabolic and endocrine disorders. The company's strong focus on research and development drives its efforts in bringing novel treatment options to market.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!